Literature DB >> 2299591

Effects of chronic administration of nicotine on prolactin release in the rat: inactivation of prolactin response by repeated injections of nicotine.

B A Hulihan-Giblin1, M D Lumpkin, K J Kellar.   

Abstract

The effects of chronic injections of nicotine on nicotine-induced prolactin release in the rat were measured and compared to the effects of this treatment on [3H]acetylcholine binding to nicotinic cholinergic sites in the hypothalamus. Treatment with nicotine for 10 days (s.c. injections twice daily) abolished prolactin release in response to an acute i.v. injection of nicotine given 2, 6 or 8 days after the last of the chronic injections of nicotine. At each of these time points, the binding of [3H]acetylcholine in the hypothalamus from rats treated chronically with nicotine was significantly higher than in the hypothalamus from control rats. By 14 days after the last chronic injection of nicotine, the prolactin response to an acute injection of nicotine was restored. Coinciding with the return of the nicotine-induced prolactin response, the binding of [3H]acetylcholine had returned to control values. These results are consistent with the hypothesis that nicotine inactivates nicotinic cholinergic receptors in brain by an allosteric mechanism, and that prolonged inactivation of nicotinic cholinergic receptors leads to their increased number.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2299591

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

Review 1.  Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond.

Authors:  Paul R Sanberg; Cecilia Vindrola-Padros; R Douglas Shytle
Journal:  Physiol Behav       Date:  2012-07-06

2.  Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline.

Authors:  Jill R Turner; Laura M Castellano; Julie A Blendy
Journal:  Nicotine Tob Res       Date:  2010-11-22       Impact factor: 4.244

3.  Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization.

Authors:  Tanuja Bordia; Carla Campos; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2010-03-03       Impact factor: 4.030

4.  Reward sensitization: effects of repeated nicotine exposure and withdrawal in mice.

Authors:  Monica R F Hilario; Jill R Turner; Julie A Blendy
Journal:  Neuropsychopharmacology       Date:  2012-07-25       Impact factor: 7.853

5.  Acute stress or corticosterone administration reduces responsiveness to nicotine: implications for a mechanism of conditioned tolerance.

Authors:  A R Caggiula; L H Epstein; S M Antelman; S Saylor; S Knopf; K A Perkins; R Stiller
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Characterization of human alpha4beta2 neuronal nicotinic receptors stably expressed in SH-EP1 cells.

Authors:  M A Pacheco; T E Pastoor; R J Lukas; L Wecker
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

7.  Effects of chronic drug treatments on increases in intracellular calcium mediated by nicotinic acetylcholine receptors in SH-SY5Y cells.

Authors:  Diana L Ridley; Jukka Pakkanen; Susan Wonnacott
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

8.  Acute tolerance to the locomotor stimulant effects of nicotine in the rat.

Authors:  R L Hakan; C Ksir
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

9.  Dissociation of tolerance and nicotine withdrawal-associated deficits in contextual fear.

Authors:  Thomas J Gould; Derek S Wilkinson; Emre Yildirim; Julie A Blendy; Michael D Adoff
Journal:  Brain Res       Date:  2014-03-02       Impact factor: 3.252

10.  Adrenalectomy reverses chronic injection-induced tolerance to nicotine.

Authors:  E A Grun; J R Pauly; A C Collins
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.